Immunogen (NASDAQ: IMGN) reported Q2 EPS of ($0.39), $0.01 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $13.85 million versus the consensus estimate of $18.1 million.

For 2017, ImmunoGen expects:

• revenues between $70 million and $75 million, which includes $28 million of expected upfront and milestone fees from our partners;
• operating expenses between $175 million and $180 million; and
• cash and marketable securities at December 31, 2017 between $35 million and $40 million.

For earnings history and earnings-related data on Immunogen (IMGN) click here.